2. Vitamin D Related/Nuclear Receptor Epigenetics PI3K/Akt/mTOR
  3. Estrogen Receptor/ERR Histone Methyltransferase Thyroid Hormone Receptor PI3K Akt mTOR Androgen Receptor
  4. 4,4'-Sulfonyldiphenol

4,4'-Sulfonyldiphenol  (Synonyms: Bisphenol S; Bis(4-hydroxyphenyl) sulfone)

Cat. No.: HY-W011927 Purity: 99.44%
COA
SDS
Handling Instructions Technical Support

4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.

For research use only. We do not sell to patients.

4,4'-Sulfonyldiphenol

4,4'-Sulfonyldiphenol Chemical Structure

CAS No. : 80-09-1

Size Price Stock Quantity
25 g In-stock
50 g In-stock
100 g In-stock
500 g In-stock
1 kg In-stock

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 4,4'-Sulfonyldiphenol:

4,4'-Sulfonyldiphenol Related Antibodies

Top Publications Citing Use of Products

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms
Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

View All Histone Methyltransferase Isoform Specific Products:

View All Isoforms
EZH1 EZH2 DOT1L SMYD2 SMYD3 SUV39H2/KMT1B EHMT2/G9a/KMT1C EHMT1/GLP/KMT1D ASH1L/KMT2H SETDB1/KMT2G SETD2/KMT3A NSD2/MMSET/WHSC1 SETD7/KMT7 SETD8/KMT5A PRMT1 PRMT3 PRMT4 PRMT5 PRMT6 PRMT7 PRMT8

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All mTOR Isoform Specific Products:

View All Isoforms
mTOR mTORC1 mTORC2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae[1][2][3][4][5][6][7].

In Vitro

4,4'-Sulfonyldiphenol (0-50 μM) induces thyroid hormone (TH)-dependent GH3 cell proliferation, and inhibits T3 (HY-A0070A) induction in the presence of T3[3].
4,4'-Sulfonyldiphenol (100 μM, 24 h) Significantly increases lipid deposition in AML12 and primary hepatocytes via the JunB/ATF3 axis[4].
4,4'-Sulfonyldiphenol (0.001-100 μM, 4-24 h) promotes the proliferation and migration of U-87 MG cells at a concentration of 0.1 µM and appears to be linked to the activation of the EZH2-mediated PI3K/ AKT/mTOR pathway[6].
4,4'-Sulfonyldiphenol (0.01-1 μM, 0-24 h) exhibits enhanced formation of foam cells with oxidized lowdensity lipoprotein (oxLDL) in macrophages[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4,4'-Sulfonyldiphenol Related Antibodies

Cell Proliferation Assay[6]

Cell Line: U-87 MG cells
Concentration: 0, 0.001, 0.01, 0.1, 1, 10 and 100 μM
Incubation Time: 4 and 8 h
Result: Significantly increased the proliferation rate at 0.1 μM, and the effect was more significant after 8 hours of treatment than after 4 hours.

Cell Migration Assay [6]

Cell Line: U-87 MG cells
Concentration: 0.1 μM
Incubation Time: 0, 2, 4, 6, 8, 10 and 12 h
Result: Significantly increased the mobility within 12 hours.

Cell Invasion Assay[6]

Cell Line: U-87 MG cells
Concentration: 0.1, 1 and 10 μM
Incubation Time: 24 h
Result: Induced glioblastoma invasion in U-87 MG cells.

RT-PCR[6]

Cell Line: U-87 MG cells
Concentration: 0.1 μM
Incubation Time: 4 and 8 h
Result: Increased the mRNA level of EZH2.

Western Blot Analysis[6]

Cell Line: U-87 MG cells
Concentration: 0.1 μM
Incubation Time: 4 and 8 h
Result: Increased the expression of EZH2, p-PI3K, p-AKT, p-mTOR and p-4E-BP1.
Decreased the expression of PIK3IP1.
In Vivo

4,4'-Sulfonyldiphenol (2-2000 μg/kg, p.o., starting on pregnancy day 9 through lactation day 2 or 20 ) alters the growth of the mammary epithelium and sensitizes males to additional estrogen exposures encountered at puberty in mice[1].
4,4'-Sulfonyldiphenol (0.2-50 μg/kg, p.o., once daily beginning at gestational day 0 and continuing in offspring up to 23-weeks old) can be an obesogen at low doses and after perinatal and chronic exposure for the male mice[2].
4,4'-Sulfonyldiphenol (0-10 μM, single dose) induces TH-response gene transcription in Pelophylax nigromaculatus tadpoles, but in the presence of T3 altered T3-induced gene transcription in a biphasic concentration-response manner[3].
4,4'-Sulfonyldiphenol (0.1-1 mg/kg, i.g., once daily for 3 months) induces mice to show significant lipid deposition in the liver and dyslipidemia and were predisposed to metabolic dysfunction-associated steatotic liver disease (MASLD)[4].
4,4'-Sulfonyldiphenol (0.1-1 mg/kg, i.g., once daily for 3 months) induces intestinal inflammation via altering gut microbiome in mice[5].
4,4'-Sulfonyldiphenol (0-100 μg/L, for 15-45 days) accelerates the progression of atherosclerotic cardiovascular disease (ASCVD) using zebrafish embryo-larvae as a model[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Long-term and short-term exposure effect assessment established in female CD-1 mice[1]
Dosage: 2 and 200 μg/kg (long-term); 2, 200, and 2000 μg/kg (short-term)
Administration: Oral administration (p.o.), once daily starting on pregnancy day 9 through lactation day 20 (long-term) and starting on pregnancy day 9 through lactation day 2 (short-term)
Result: Showed signs of ductal formation in the mammary gland and significantly enlarged the intercellular spaces between the tissues.
Increased ERα expression in epithelial cells and dose-dependently decreased AR expression in the stroma.
Increased the right duct area in all groups, and the left duct area also increased significantly in the high-dose group.
Altered the response of male mice to a pre-pubertal estrogen challenge.
Animal Model: High fat diet model established in pregnant C57Bl/6J mice[2]
Dosage: 0.2, 1.5, 50 µg/kg
Administration: Oral administration (p.o.) with water, once daily beginning at gestational day 0 and continuing in offspring up to 23-weeks old
Result: Significant increased in body weight and fat mass on a high-fat diet.
Had no effect on the food intake and energy expenditure.
Exhibited a weak but significant hypercholesterolemia with a fold increase of 1.21 and 1.29 at 1.5 and 50 µg/kg, respectively.
Showed a significant decrease of the AUC (increase of blood TG clearance).
Significantly increased the calculated HOMA-IR index in mice exposed to 1.5 and 50 µg/kg.
Induced a significant overexpression of SOCS3 mRNA and a significant mRNA down-regulation of INSR and adiponectin.
Induced a weak but significant decrease in mRNA expression of HSL and PPARγ genes in adipose tissue of male mice fed with a HFD.
Animal Model: MASLD model established in 7-week-old C57BL/6 male mice[4]
Dosage: 0.1 and 1 mg/kg
Administration: Oral gavage (i.g.), once daily for 3 months
Result: Induced MASLD phenotype: elevated LDL, increased NEFA, and elevated ALT.
Showed obvious lipid droplet accumulation.
Animal Model: Intestinal inflammation model established in 6-7 week old male C57BL/6 mice[5]
Dosage: 0.1 and 1 mg/kg alone and 1 mg/kg with antibiotic cocktail (ABX)
Administration: Oral gavage (i.g.), once daily for 3 months alone and also for 3 months, during the exposure process, every two-week ABX treatment was followed by a two-week recovery in cycles
Result: Led to typical features of intestinal inflammation: significant shortening of colon length, tissue pathological damage, increased immune cell infiltration and apoptosis.
Induced bacterial imbalance, increasing pro-inflammatory bacteria and decreasing anti-inflammatory bacteria.
Caused an increase in arachidonic acid (pro-inflammatory) and a decrease in madecainic acid (anti-inflammatory).
Normalized intestinal inflammation, improved metabolism after antibiotic intervention.
Molecular Weight

250.28

Formula

C12H10O4S
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

O=S(C1=CC=C(O)C=C1)(C2=CC=C(O)C=C2)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (399.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.9955 mL 19.9776 mL 39.9552 mL
5 mM 0.7991 mL 3.9955 mL 7.9911 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (9.99 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (9.99 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.81%

SDS (393 KB)

COA (248 KB) LCMS (88 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.9955 mL 19.9776 mL 39.9553 mL 99.8881 mL
5 mM 0.7991 mL 3.9955 mL 7.9911 mL 19.9776 mL
10 mM 0.3996 mL 1.9978 mL 3.9955 mL 9.9888 mL
15 mM 0.2664 mL 1.3318 mL 2.6637 mL 6.6592 mL
20 mM 0.1998 mL 0.9989 mL 1.9978 mL 4.9944 mL
25 mM 0.1598 mL 0.7991 mL 1.5982 mL 3.9955 mL
30 mM 0.1332 mL 0.6659 mL 1.3318 mL 3.3296 mL
40 mM 0.0999 mL 0.4994 mL 0.9989 mL 2.4972 mL
50 mM 0.0799 mL 0.3996 mL 0.7991 mL 1.9978 mL
60 mM 0.0666 mL 0.3330 mL 0.6659 mL 1.6648 mL
80 mM 0.0499 mL 0.2497 mL 0.4994 mL 1.2486 mL
100 mM 0.0400 mL 0.1998 mL 0.3996 mL 0.9989 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

4,4'-Sulfonyldiphenol Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

4,4'-Sulfonyldiphenol80-09-1Bisphenol SBis(4-hydroxyphenyl) sulfoneEstrogen Receptor/ERRHistone MethyltransferaseThyroid Hormone ReceptorPI3KAktmTORAndrogen ReceptorTHRPhosphoinositide 3-kinasePKBProtein kinase BMammalian target of RapamycinEstrogen receptorEndocrine disruptorNipple retentionMammary epitheliumTwo hit modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
4,4'-Sulfonyldiphenol
Cat. No.:
HY-W011927
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.